Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Change in Cash (2019 - 2025)

Pulmonx (LUNG) reported Change in Cash of $1.1 million for Q3 2025, up 818.54% year-over-year from $118121.8 in Q3 2024, and up 18.84% on a QoQ basis from $913000.0 in Q2 2025.

Pulmonx (LUNG) has 7 years of Change in Cash data on file, last reported at $1.1 million in Q3 2025.

  • Quarterly Change in Cash rose 818.54% year-over-year to $1.1 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $13.2 million (up 141.88% YoY) and the FY2024 annual result came in at -$12.6 million, up 30.58% from the prior year.
  • Change in Cash improved to $1.1 million in Q3 2025 per LUNG's latest filing, from $913000.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $8.7 million in Q1 2023 and bottomed at -$39.6 million in Q4 2021.
  • The 5-year median for Change in Cash is -$8.6 million (2023), against an average of -$8.2 million.
  • The widest annual swing landed in 2021, when Change in Cash sank 1406.63%; it then surged 818.54% in 2025.
  • Tracing LUNG's Change in Cash over 5 years: stood at -$39.6 million in 2021, then jumped by 73.06% to -$10.7 million in 2022, then slipped by 6.85% to -$11.4 million in 2023, then soared by 166.61% to $7.6 million in 2024, then sank by 85.71% to $1.1 million in 2025.
  • Per Business Quant, the three latest LUNG Change in Cash figures stand at $1.1 million (Q3 2025), $913000.0 (Q2 2025), and $3.6 million (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -1.72 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -1.13 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -136.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -504.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -492.00 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 199.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -2.23 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 15.90 Mn
10 Pulmonx 67.30 Mn -2.45 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 1.09 Mn
Jun 30, 2025 913,000.00
Mar 31, 2025 3.65 Mn
Dec 31, 2024 7.59 Mn
Sep 30, 2024 -151,000.00
Jun 30, 2024 -6.67 Mn
Mar 31, 2024 -13.39 Mn
Dec 31, 2023 -11.40 Mn
Sep 30, 2023 -6.87 Mn
Jun 30, 2023 -8.59 Mn
Mar 31, 2023 8.67 Mn
Dec 31, 2022 -10.67 Mn
Sep 30, 2022 -9.55 Mn
Jun 30, 2022 -7.22 Mn
Mar 31, 2022 -19.31 Mn
Dec 31, 2021 -39.60 Mn
Sep 30, 2021 -10.63 Mn
Jun 30, 2021 -10.58 Mn
Mar 31, 2021 -22.28 Mn
Dec 31, 2020 191.76 Mn
Sep 30, 2020 -3.54 Mn
Jun 30, 2020 27.11 Mn
Mar 31, 2020 1.71 Mn
Dec 31, 2019 -963,000.00